DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?

被引：2

作者：

Christensen, Mikkel ^{[2
]}

Knop, Filip K. ^{[1
]}

机构：

[1] Univ Copenhagen, Diabet Res Div, Dept Internal Med, Gentofte Hosp, DK-2900 Hellerup, Denmark

[2] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, DK-2400 Copenhagen, Denmark

来源：

NATURE REVIEWS ENDOCRINOLOGY | 2012年 / 8卷 / 10期

关键词：

HYPOGLYCEMIA; ASSOCIATION;

D O I：

10.1038/nrendo.2012.163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.

引用

页码：576 / 578

页数：3

共 50 条

[1] Add-on to metformin in T2DM—linagliptin or glimepiride?
Mikkel Christensen
Filip K. Knop
Nature Reviews Endocrinology, 2012, 8 : 576 - 578
[2] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
Ridderstrale, Martin
Andersen, Knut Robert
Zeller, Cordula
Kim, Gabriel
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2014, 63 : A70 - A70
[3] Empaglifl ozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 4 Years in Patients with Type 2 Diabetes (T2DM)
Ridderstrale, Martin
Robert, Knut
Toorawa, Andersen
Woerle, Hans J.
Salsali, Afshin
DIABETES, 2016, 65 : A47 - A48
[4] Empaglilozin compared with glimepiride as add-on to metformin for 2 years in patients with type 2 diabetes
Ridderstrale, M.
Andersen, K. R.
Zeller, C.
Kim, G.
Woerle, H. J.
Broedl, U. C.
DIABETOLOGIA, 2014, 57 : S7 - S8
[5] Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus
Chilton, Robert
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (04) : 345 - 349
[6] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
Du, Jin
Liang, Li
Fang, Hui
Xu, Fengmei
Li, Wei
Shen, Liya
Mu, Yiming
DIABETES, 2016, 65 : A293 - A293
[7] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
Toplak, H
Vercruysse, F
Sun, X
Fitchet, M
INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
[8] Combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with Type 2 diabetes
Defronzo, R. A.
Lewin, A.
Patel, S.
Liu, D.
Kaste, R.
Woerle, H. J.
Broedl, U. C.
DIABETIC MEDICINE, 2015, 32 : 90 - 90
[9] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
Frias, Juan P.
Gonzalez-Galvez, Guillermo
Johnsson, Eva K.
Maaske, Jill
Peters, Anne
DIABETES, 2018, 67
[10] Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Region in a 24-Week Randomized Trial
Wanner, Christoph
Naderali, Ebrahim
Maldonaldo, Mario
Del Parigi, Angelo
Toorawa, Robert
Lee, Christopher
DIABETES, 2016, 65 : A288 - A289

← 1 2 3 4 5 →